The Clorox Company $CLX Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC reduced its position in shares of The Clorox Company (NYSE:CLX - Free Report) by 95.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,346 shares of the company's stock after selling 107,345 shares during the period. Allspring Global Investments Holdings LLC's holdings in Clorox were worth $660,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in shares of Clorox by 0.6% during the 1st quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 13,266 shares of the company's stock valued at $1,953,000 after acquiring an additional 73 shares in the last quarter. Horizon Investments LLC grew its stake in Clorox by 4.4% during the 1st quarter. Horizon Investments LLC now owns 1,768 shares of the company's stock worth $258,000 after buying an additional 75 shares during the last quarter. Sfmg LLC grew its stake in Clorox by 2.8% during the 1st quarter. Sfmg LLC now owns 2,780 shares of the company's stock worth $409,000 after buying an additional 76 shares during the last quarter. Hancock Whitney Corp grew its stake in Clorox by 4.3% during the 1st quarter. Hancock Whitney Corp now owns 2,064 shares of the company's stock worth $304,000 after buying an additional 86 shares during the last quarter. Finally, Brown Lisle Cummings Inc. grew its stake in Clorox by 4.3% during the 2nd quarter. Brown Lisle Cummings Inc. now owns 2,136 shares of the company's stock worth $256,000 after buying an additional 89 shares during the last quarter. 78.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Clorox

In other news, COO Eric H. Reynolds sold 15,041 shares of the company's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the completion of the sale, the chief operating officer directly owned 54,221 shares of the company's stock, valued at $6,711,475.38. This represents a 21.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.63% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages recently commented on CLX. Morgan Stanley lowered their price objective on Clorox from $150.00 to $137.00 and set an "equal weight" rating for the company in a research note on Friday, August 1st. Weiss Ratings reissued a "hold (c-)" rating on shares of Clorox in a research note on Tuesday, October 14th. The Goldman Sachs Group decreased their price target on Clorox from $115.00 to $110.00 and set a "sell" rating for the company in a research note on Wednesday, October 1st. Citigroup decreased their price target on Clorox from $135.00 to $130.00 and set a "neutral" rating for the company in a research note on Wednesday, October 8th. Finally, UBS Group decreased their price target on Clorox from $134.00 to $128.00 and set a "neutral" rating for the company in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, twelve have assigned a Hold rating and four have assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Reduce" and an average target price of $130.20.

Clorox Trading Down 1.5%

Shares of CLX stock opened at $116.37 on Friday. The stock has a 50-day simple moving average of $121.30 and a 200 day simple moving average of $127.15. The Clorox Company has a fifty-two week low of $116.32 and a fifty-two week high of $171.37. The stock has a market capitalization of $14.17 billion, a P/E ratio of 17.85, a P/E/G ratio of 0.98 and a beta of 0.52. The company has a quick ratio of 0.57, a current ratio of 0.84 and a debt-to-equity ratio of 5.15.

Clorox (NYSE:CLX - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.24 by $0.63. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The business had revenue of $1.99 billion during the quarter, compared to analysts' expectations of $1.94 billion. During the same quarter last year, the business posted $1.82 earnings per share. The company's quarterly revenue was up 4.5% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. On average, sell-side analysts expect that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Clorox Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, November 6th. Stockholders of record on Wednesday, October 22nd will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 4.3%. The ex-dividend date of this dividend is Wednesday, October 22nd. Clorox's dividend payout ratio is currently 76.07%.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.